Xiaoxian Zhao, Feng Lin and Eric D. Hsi*
CD6 is one of the first discovered lymphocyte receptors. It is expressed on all T cells, a NK cell subset, and B-lymphocyte B1a subsets. CD6 is involved in cell-to-cell interaction and modulation of adaptive immune responses. It is also implicated in the pathogenesis of a variety of immune-mediated conditions. CD6 and its two major known ligands (CD166 and CD318) have emerged as new therapeutic targets for autoimmune diseases. Recent studies explored the distribution of CD6 in both T-cell lymphomas and aggressive NK/T cell neoplasms, and evaluated the activities of CD6-antibody drug conjugate in both in vitro and in vivo mouse models for these malignancies. In this mini-review, we highlight the current understanding of CD6 as a therapeutic target in autoimmune disease, T cell lymphoma and aggressive NK/T cell neoplasms.
PDFShare this article
Journal of Blood & Lymph received 443 citations as per Google Scholar report
